The 5-year results of the DRCR.net Protocol S study support the use of ranibizumab or panretinal photocoagulation as viable treatments for proliferative diabetic retinopathy.
The Diabetic Retinopathy Clinical Research Network evaluated 394 study eyes with proliferative diabetic retinopathy in a multicenter randomized clinical trial. Researchers evaluated the mean change in visual acuity in patients treated with either intravitreous Lucentis (ranibizumab, Genentech) or panretinal photocoagulation (PRP).
Left untreated, proliferative diabetic retinopathy can lead to blindness. The results of the
Uncategorized